C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Mye
11 Ottobre 2023 - 1:00PM
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage
biopharmaceutical company dedicated to advancing targeted protein
degradation science to develop a new generation of small-molecule
medicines and transform how disease is treated, today announced
plans to share data from the Phase 1 dose escalation portions of
the ongoing Phase 1/2 trials of CFT7455 and CFT8634. The CFT8634
Phase 1 dose escalation data has been accepted as a poster
presentation at the Connective Tissue Oncology Society (CTOS)
Annual Meeting taking place from November 1 – 4, 2023 in Dublin,
Ireland. C4T will host a company-sponsored event on December 12,
2023, to share the CFT7455 dose escalation data in
relapsed/refractory multiple myeloma (R/R MM).
Upcoming CFT8634 Clinical
Data
The Phase 1/2 trial is designed to characterize safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and
evidence of anti-tumor activity of CFT8634 based on RECIST 1.1
criteria. As of August 29, 2023, 32 patients were enrolled across
six dose escalation cohorts using a daily dosing schedule.
CTOS Presentation Details
Title: Initial results from a Phase 1 study of CFT8634, a novel
bifunctional degradation activating compound (BiDAC) degrader of
BRD9, in synovial sarcoma and SMARCB1-null tumorsFormat: Poster
PresentationTime: Thursday, November 2, 2023; 5:30 PM – 6:30 PM IST
(9:00 AM EST)Presenter: Mark Agulnik, M.D., sarcoma section chief,
department of medical oncology and therapeutics research, City of
Hope
Data included in the poster presentation will be PK, PD, safety
and RECIST criteria efficacy measures.
Upcoming CFT7455 Clinical Data
The Phase 1/2 trial is designed to characterize the safety,
tolerability, PK, PD and anti-tumor activity of CFT7455 in patients
with R/R MM or relapsed/refractory non-Hodgkin’s lymphoma (R/R
NHL). The Phase 1 dose escalation portion of the ongoing Phase 1/2
trial has utilized a 14 days on/14 days off dosing schedule within
which both daily dosing and Monday/Wednesday/Friday dosing were
explored. C4T has completed the Phase 1 dose escalation for CFT7455
as a monotherapy in R/R MM using a 14 days on/14 days off dosing
schedule; 22 patients were enrolled across five dose escalation
cohorts for this portion of the study. Enrollment continues for the
Phase 1 dose escalation evaluating CFT7455 with dexamethasone in
R/R MM and as a monotherapy in R/R NHL.
At a company-sponsored event on December 12, 2023, C4T plans to
present Phase 1 dose escalation data that focuses on the CFT7455
monotherapy regimen in R/R MM.
Upcoming Investor Conferences
The company is planning to participate in the following upcoming
investor conferences:
- November 8, 2023: Management will participate in the UBS
Biopharma Conference taking place in Miami, FL.
- November 14, 2023: Management will participate in the Stifel
2023 Conference taking place in New York, NY.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage
biopharmaceutical company dedicated to delivering on the promise of
targeted protein degradation science to create a new generation of
medicines that transforms patients’ lives. C4T is leveraging its
TORPEDO® platform to efficiently design and optimize
small-molecule medicines that harness the body’s natural protein
recycling system to rapidly degrade disease-causing proteins,
offering the potential to overcome drug resistance, drug
undruggable targets and improve patient outcomes. C4T is advancing
multiple targeted oncology programs to the clinic and expanding its
research platform to deliver the next wave of medicines for
difficult-to-treat diseases. For more information, please
visit www.c4therapeutics.com.
About CFT7455
CFT7455 is an orally bioavailable MonoDAC™ degrader designed to
be highly potent and selective against its intended targets of
Ikaros (IKZF1) and Aiolos (IKZF3). CFT7455 binds with high affinity
to the E3 ligase adapter protein, cereblon, to target and degrade
IKZF1/3 for the treatment of multiple myeloma and non-Hodgkin's
lymphomas, including peripheral T cell lymphoma and mantle cell
lymphoma. In early clinical data, CFT7455 demonstrated deep and
durable degradation of IKZF1/3. C4T is enrolling patients in its
ongoing Phase 1/2 clinical trial of CFT7455. More information about
this trial may be accessed at www.clinicaltrials.gov (identifier:
NCT04756726).
About CFT8634
CFT8634 is an orally bioavailable BiDAC™ degrader designed to be
potent and selective against BRD9. BRD9 was previously considered
an undruggable target due to the inability of bromodomain
inhibitors to effectively treat cancers dependent on BRD9. Unlike
BRD9 inhibition, BRD9 degradation has been shown to be efficacious
in pre-clinical models of synovial sarcoma. C4T is enrolling
patients in its ongoing Phase 1/2 clinical trial of CFT8634 for the
treatment of synovial sarcoma and SMARCB1-null solid tumors. More
information about this trial may be accessed at
www.clinicaltrials.gov (identifier: NCT05355753).
Forward-Looking Statements
This press release contains “forward-looking statements” of C4
Therapeutics, Inc. within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements may
include, but may not be limited to, express or implied statements
regarding our ability to develop potential therapies for patients;
the design and potential efficacy of our therapeutic approaches;
the status of, progress on and data from our clinical trials; the
predictive capability of our TORPEDO® platform in the
development of novel, selective, orally bioavailable BiDAC™ and
MonoDAC™ degraders; the potential timing, design and advancement of
our preclinical studies and clinical trials, including the
potential timing for and receipt of regulatory authorization
related to clinical trials and other clinical development
activities including clinical trial commencement; our ability and
the potential to successfully manufacture and supply our product
candidates for clinical trials; our ability to replicate results
achieved in our preclinical studies or clinical trials in any
future studies or trials; regulatory developments in the United
States and foreign countries; and our ability to fund our future
operations. Any forward-looking statements in this press release
are based on management’s current expectations and beliefs of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: uncertainties related to the initiation,
timing, advancement and conduct of preclinical and clinical studies
and other development requirements for our product candidates; the
risk that any one or more of our product candidates will cost more
to develop or may not be successfully developed and commercialized;
the risk that the results of preclinical studies and/or clinical
trials will or will not be predictive of results in connection with
future studies or trials. For a discussion of these and other risks
and uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or
Quarterly Report on Form 10-Q, as filed with the Securities and
Exchange Commission. All information in this press release is as of
the date of the release, and C4 Therapeutics undertakes no duty to
update this information unless required by law.
Contacts:Investors: Courtney SolbergSenior
Manager, Investor RelationsCSolberg@c4therapeutics.com
Media: Loraine Spreen Senior Director, Corporate
Communications & Patient
Advocacy LSpreen@c4therapeutics.com
Grafico Azioni C4 Therapeutics (NASDAQ:CCCC)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni C4 Therapeutics (NASDAQ:CCCC)
Storico
Da Mag 2023 a Mag 2024